nova página do texto(beta)
Inglês (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por email
Citado por SciELO 
Similares em
SciELO 
Permalink
Introduction
Acute promyelocytic leukemia (APL) is a neoplasm characterized by the blockage of myeloid cell differentiation mainly secondary to t(15; 17) (q24.1; q21.2)1. Its prevalence is high in Latin America and the Caribbean2. Studies conducted in the United States (California and Florida) have identified that its frequency is higher in the Latino population compared to Anglo-Saxons (24.3% vs. 8.3%) or even African-Americans3,4. Unlike other types of leukemia, treatment is highly effective and based on the use of all-transretinoic acid (ATRA) which allows for the differentiation of promyelocytes to granulocytes5,6. Various cooperative groups worldwide (PETHEMA, GIMEMA, and HOVON) have identified that the most effective combination during induction is with some type of anthracycline (Daunorubicin [DAU] or Idarubicin) and more recently with arsenic trioxide (ATO)7-11. For Latin America, the International Consortium on APL (IC-APL) recommends the use of DAU mainly due to its easy access and safety profile12. Recently, Crespo-Solis et al. published the experience of using an adaptation of the IC-APL guidelines, in a health center in Mexico City, reaching a 94.4% complete remission (CR) rate and 89.1% overall survival rate13. Despite the high response rate, less than 20% of patients die prematurely, mostly due to hemorrhages14. Unfortunately, mortality is still high, especially in countries with poor access to ATRA and in patients considered as high-risk patients15-17. This risk (low, intermediate, and high) is established using the classification of the Spanish group PETHEMA (Spanish Program on Hematology Treatments) which is based on the combination of two variables; leukocyte count and platelet count, considering those cases with values above 10 × 109/L leukocytes such as high-risk patients18,19. An increasing number of factors have been assimilated to identify high-risk patients. The main ones are at the molecular level (FLT3-ITD mutation) and flow cytometry (CD56, CD2, and CD34)20,21. To improve the clinical scale, Park et al. included hemoglobin values into the risk score, known as complete blood count (CBC) score, and unlike the PETHEMA score, the risk was established with the sum of each of the different values22. The main objective of this study was to identify the utility of the two scales (PETHEMA and CBC score) on the risk of premature death of patients with APL undergoing an ATRA and DAU-based treatment as induction therapy.
Materials and methods
Study design
A retrospective, observational study in patients diagnosed with de novo APL treated at the Hematology Department of Hospital General de México from January 2001 to June 2015.
Treatment protocol
Induction
ATRA was administered for 45 days at a dose of 10 mg/10 kg of body weight, together with DAU at a dose of 45 mg/m2 of body surface area on days +2, +4, +6, and +8.
Consolidation
Three monthly blocks were used, according to the type of risk. ATRA was added to the treatment of intermediate- or high-risk patients. The consolidation scheme is described in figure 1.
Maintenance
Maintenance lasted for 2 years, based on 6-mercaptopurine at a dose of 50 mg/m2 administered orally on a daily basis and 50 mg intramuscular methotrexate on a weekly basis. Administration of ATRA took place every 3 months for a period of 15 days.
Dexamethasone 8 mg was added preventively to the treatment of high-risk patients 3 times a day. In case of suspicion of differentiation syndrome, ATRA administration was suspended until improvement of symptoms.
Risk scales
Under the PETHEMA classification, high risk was considered: leukocytes ≥ 10 × 109/L; intermediate risk: leukocytes < 10 × 109/L and/or platelets ≤ 40 × 109/L; and low risk if leukocytes < 10 × 109/L and/or platelets > 40 × 109/L18,19.
The CBC scoring system assigns 1 point to each variable: leukocytes ≥ 10 × 109/L, platelets ≤ 40 × 109/L, hemoglobin ≤ 8 g/dL; and the level of risk is due to the sum of points: low (0 points), intermediate (1 point), and high (2-3 points).
Statistical analysis
Data were analyzed with IBM SPSS statistical software, version 20.0. For the analysis of the prognostic impact of the scores as well as the different variables on mortality, a multivariate analysis was performed, identifying the risk (OR) for each risk variable. Survival curves were obtained by the Kaplan-Meier method. The results whose hypothesis contrast test yielded p ≤ 0.05 were deemed statistically significant.
Results
From January 2001 to June 2015, 82 patients with APL were analyzed and included in the institutional protocol, HGMLAP-2001. Only three cases were excluded, due to the lack of information for the final analysis. ATRA administration was initiated early in all patients accompanied by transfusion support.
Patient's characteristics
Among the 79 eligible patients, 58.2% were female (n = 46); the average age was 34 years (range 17-57 years). Only 10% of patients were older than 50 years at the time of diagnosis.
The mean white blood cell count at diagnosis was 14.54 × 109/L (range 0.38-204 × 109/L), but the majority were with < 10 × 109/L (69.6%), 11.3% of the cases showed values above 50 × 109/L at the time of diagnosis. The mean platelet volume was 39.21 × 109/L (range 4-272 × 109/L); being mostly < 50 × 109/L (73.8%).
The main clinical manifestation at diagnosis was hemorrhage followed by anemic syndrome. No splenomegaly or nodal growth was documented in any patient. Among the 80 eligible cases, only 3.8% (n = 3) presented a creatinine value above 1.5 mg/dL at diagnosis and 7.5% (n = 6) presented bilirubin levels > 2 mg/dL isolated or in conjunction with elevated aspartate aminotransferase or alanine transaminase levels.
The qualitative and quantitative features of the studied population are described in tables 1 and 2, respectively.
Table 1 Qualitative features of patients with APL treated at Hospital General de México between 2001 and 2015
| Feature | n (%) |
|---|---|
| Total patients | 79 |
| Gender | |
| Males | 33 (41.8) |
| Females | 46 (58.2) |
| Clinical manifestations | |
| ATRA syndrome | 12 (15.2) |
| Febrile neutropenia | 50 (63.3) |
| Mild hemorrhage | 27 (34.2) |
| Moderate-severe hemorrhage | 48 (60.8) |
| Central nervous system hemorrhage | 4 (5.1) |
| PETHEMA score | |
| Low risk | 19 (24.1) |
| Intermediate risk | 36 (45.6) |
| High risk | 24 (30.4) |
| CBC score | |
| Low risk (0 points) | 12 (15.2) |
| Intermediate risk (1 point) | 27 (34.2) |
| High risk (2 and 3 points) | 40 (50.6) |
APL: acute promyelocytic leukemia; CBC: complete blood count.
Classification according to risk
Table 1 shows the number of patients classified in each risk level according to the PETHEMA scales and CBC score.
Table 2 Quantitative features of patients with APL treated at Hospital General de México between 2001 and 2015
| Analyte | Mean (range) | Standard deviation |
|---|---|---|
| Age (range) | 34 (17-57) | ± 11.8 |
| Leukocytes (×109/L) | 14.54 (0.38-204) | ± 30.18 |
| n cases with < 10 (%) | 55 (69.6) | |
| n cases with ≥ 10 (%) | 24 (30.4) | |
| Hemoglobin (g/dL) | 8.79 (3.3-17.9) | ± 2.8 |
| n cases with ≤ 8 (%) | 51 (64.6) | |
| n cases with > 8 (%) | 28 (35.4) | |
| Platelets (×109/L) | 39.21 (4-272) | ± 47.15 |
| n cases with ≤ 40 (%) | 54 (68.4) | |
| n cases with > 40 (%) | 25 (31.6) | |
| Albumin (g/dL) | 3.5 (1.8-5.1) | ± 0.6 |
| AST (UI/L) | 33.8 (10-141) | ± 25.6 |
| ALT (UI/L) | 35.1 (10-117) | ± 24.6 |
| Alkaline phosphatase (UI/L) | 88.7 (35-371) | ± 52.4 |
| Lactate dehydrogenase (UI/L) | 327 (100-1272) | ± 211.5 |
| Bilirubin (mg/dL) | 0.99 (0.32-5.4) | ± 0.72 |
| Creatinine (mg/dL) | 0.79 (0.3-1.6) | ± 0.25 |
| Urea (mg/dL) | 30.05 (6.4-76.3) | ± 13.09 |
| PT (s) | 14.9 (11.3-25.9) | ± 2.7 |
| aPTT (s) | 26.3 (18.2-49.8) | ± 4.9 |
| TT (s) | 22.4 (12-117) | ± 13.7 |
| Fibrinogen (g/dL) | 227.1 (0-671) | ± 129.6 |
PT: prothrombin time; aPPT: activated partial thromboplastin time; TT: thrombin time; APL: acute promyelocytic leukemia; ALT: alanine transaminase; AST: aspartate aminotransferase.
Treatment response
The rate of CRs was 74.7% of cases (n = 59), with a therapeutic failure of 25.3% of cases (n = 20). During induction therapy, 62.5% of patients (n = 50) developed febrile neutropenia, with 16% of patients (n = 8) dying from sepsis.
The differentiation syndrome was perceived in 15% of patients (n = 12), with 3 patients (3.8%) dying from this complication.
Survival
At a mean follow-up of 2.8 years (112 days-13.4 years), the overall survival rate was 76%. The overall mortality rate was 25.3% (n = 21). When analyzing the survival rate according to each of the risk groups, the patients considered as low risk by the PETHEMA scale showed a higher survival rate (86%) compared to those high-risk patients (58%). When analyzing the survival rate according to the CBC score, patients without any risk score showed a higher survival rate (92%), unlike those patients who scored different risk factors (60% in those patients with three points). Survival according to each of the PETHEMA and CBC risk groups is described in figure 2.
Factors associated with mortality
Individually, severe thrombocytopenia (< 40 × 109/L) as well as prolonged thrombin time behaved as a risk factor for death, but elevated serum fibrinogen levels also behaved as an independent risk factor for premature and late death. Both PETHEMA and CBC scores behaved as a global risk factor, but the latter allowed patients to be better distinguished. Table 3 describes the risk value of the different variables for both premature and late death.
Table 3 Risk value for premature and late death of the different variables
| Variable | Risk group | p value | Mortality OR (confidence interval at 95%) | 30-day mortality OR (confidence interval at 95%) |
|---|---|---|---|---|
| Hemoglobin | < 8 g/dL | 0.0739 | 2.5731 (0.9127-7.2543) | 0.8425 (0.2819-2.5177) |
| Leukocytes | > 10 × 109/L | 0.2822 | 0.5581 (0.1928-1.6157) | 1.3333 (0.4282-4.1519) |
| Platelets | < 40 × 109/L | 0.0747 | 3.3694 (0.8858-12.8167) | 0.6007 (0.1742-2.0717) |
| TT | > 27 s | 0.0352* | 3.3629 (1.0939-12.1316) | 1.4074 (0.4775-4.1478) |
| PT | > 14 s | 0.1583 | 2.2588 (0.7282-7.0067) | 1.5158 (0.4744-4.8436) |
| aPTT | > 26 s | 0.6372 | 1.5652 (0.3947-6.2063) | 2.3765 (0.7799-7.2420) |
| Fibrinogen | > 350 g/dL | 0.0130* | 3.8077 (1.3250-10.921) | 3.5250 (1.1550-10.7577) |
| PETHEMA score | High risk | 0.053 | 7.7727 (0.9668-62.4879) | 2.8333 (0.5851-13.7203) |
| CBC score | High risk (2-3 points) | 0.113 | 10.1485 (0.5737-179.5231) | 3.4510 (0.4131-28.8311) |
*Considering p ≤ 0.05 as statistically significant.
PT: prothrombin time; aPPT: activated partial thromboplastin time; TT: thrombin time; CBC: complete blood count.
Association between CBC and PETHEMA score
When analyzing the risk groups, most patients were in the intermediate-risk group (n = 36, 45.6%) followed by the high-risk group (n = 24, 30.4%) in the PETHEMA score. However, when searching for the correlation between the two scales, the patients considered as low or high risk for the PETHEMA score had 0-3 factors for the CBC score, respectively. A greater discrepancy was registered in those patients who had between one and two risk factors, as they were distributed between the intermediate- and high-risk group of the PETHEMA score, respectively.
Discussion and conclusions
APL is a major hematological emergency, due to its high risk of death at the time of diagnosis due to a hemorrhagic event. Early administration of ATRA together with intensive transfusion support is the main strategies for reducing mortality23. Mortality associated with leukemia was lower compared to our historical record, mainly occurring in high-risk patients.
When comparing the two scales, similarity was only identified in the low-risk groups (low-risk PETHEMA or patients with zero CBC score, that is, without relevant biochemical alterations) as cases were identified in the group of intermediate-risk patients with scores 1 and 2 in the CBC scale. The upper section of table 2 is extremely important to understand this point: two-thirds of the analyzed population (64.6%) had hemoglobin values below the cutoff point for the CBC scale; thus, placing this majority at least at intermediate risk. By integrating leukocyte and platelet values, this score is increased, which explains that for the CBC score, half of the patients had a high risk (50.6%), while only one-third of patients were at high risk (30.4%) in the PETHEMA score, as the latter scale considers only the leukocyte count alone to stratify patients as high risk.
These findings are similar to those presented by Loglisci et al. when reclassifying cases according to the CBC score. Among the cases identified as intermediate and high risk (n = 66 and n = 33), while reclassifying them according to the CBC score, most patients were identified as high-risk score 1 (n = 60) and score 2-3 (n = 47)24. When analyzing the different factors individually, thrombocytopenia severity was associated with mortality (OR 3.369, p = 0.07) as expected. This finding is similar to other series, in which the platelet count at the time of diagnosis is a determinant for hemorrhagic complications during the first 4 weeks of diagnosis25. Another risk factor that was identified for death was the level of fibrinogen. Recently, Hassan et al. identified that low levels of fibrinogen (< 1.5 g/L) were associated with a high risk of premature death26-28. These, in conjunction with prolonged hemostasis, are other factors to be considered at the time of diagnosis, especially on suspicions of a disseminated intravascular coagulation (DIC). Hence, Mitrovic et al. evaluated the usefulness of incorporating the score of the International Society on Thrombosis and Haemostasis for DIC (ISTH DC) to predict death associated with hemorrhage in 56 patients with APL29. Among the main factors were the leukocyte count (> 20 × 109/L), the performance status using the Eastern Cooperative Oncology Group (ECOG) score > 3, the level of fibrinogen (< 2 g/L), prothrombin time < 50%, and ISTH DC score > 6.29. So far, few trials have shown that elevated fibrinogen levels also affect mortality. In this research, a value of 350 mg/dL was associated with an increased risk of premature death (OR 3.525, p = 0.013). These data are similar to those reported by Wei et al., in which the presence of an elevated level of fibrinogen (> 400 mg/dL) was associated with an adverse prognosis in different hematological malignancies including APL30. Conversely, Mantha et al. analyzed several factors that were associated with premature death in five clinical trials that included the use of ATRA during induction. Among the 995 cases analyzed, both performance status and leukocyte count > 20 × 109/L were the major factors associated with premature death31.
Finally, risk stratification is also useful for identifying the efficacy of new drugs. Although the combination of ATRA with chemotherapy is still the standard treatment, the use of ATRA-ATO is especially effective in patients with low/intermediate risk32, dramatically improving hemostatic disorders33-35. However, unlike trials with ATRA, creatinine as well as performance status (ECOG) are the main factors of premature death associated with the use of ATO36.
In conclusion, the use of scores such as the CBC or PETHEMA together with individual factors, such as thrombocytopenia, allows identifying those patients with APL at risk of premature death.
